Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Achard V;Achard V; Zilli T; Zilli T
  • Source:
    Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2023 Mar; Vol. 26 (1), pp. 1-2. Date of Electronic Publication: 2022 Apr 29.
  • Publication Type:
    Editorial
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE
    • Publication Information:
      Publication: <2002->: London : Nature Publishing Group
      Original Publication: Houndmills, Basingstoke, UK : Stockton Press, c1997-
    • Subject Terms:
      Prostatic Neoplasms*/radiotherapy ; Prostatic Neoplasms*/drug therapy ; Radiotherapy, Intensity-Modulated*/adverse effects; Male ; Humans ; Dose Fractionation, Radiation ; Radiotherapy Dosage ; Treatment Outcome
    • References:
      David R, Buckby A, Kahokehr AA, Lee J, Watson DI, Leung J, et al. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. 10.1038/s41391-022-00520-x.
      Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884–90. (PMID: 10.1200/JCO.2016.71.739728296582)
      de Crevoisier R, Bayar MA, Pommier P, Muracciole X, Pene F, Dudouet P, et al. Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:1420–9. (PMID: 10.1016/j.ijrobp.2018.07.200630071296)
      Sia J, Joon DL, Viotto A, Mantle C, Quong G, Rolfo A, et al. Toxicity and long-term outcomes of dose-escalated intensity modulated radiation therapy to 74Gy for localised prostate cancer in a single Australian centre. Cancers. 2011;3:3419–31. (PMID: 10.3390/cancers3033419242129613759203)
      Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–60. (PMID: 10.1016/S1470-2045(16)30102-4273391154961874)
      Staffurth JN, Haviland JS, Wilkins A, Syndikus I, Khoo V, Bloomfield D, et al. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016). Eur Urol Oncol. 2021;4:980–92. (PMID: 10.1016/j.euo.2021.07.005344892108674146)
      Sujenthiran A, Nossiter J, Charman SC, Parry M, Dasgupta P, van der Meulen J, et al. National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2017;99:1253–60. (PMID: 10.1016/j.ijrobp.2017.07.04028974414)
      Leeman JE, Chen YH, Catalano P, Bredfeldt J, King M, Mouw KW, et al. Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials. Int J Radiat Oncol Biol Phys. 2022;112:75–82. (PMID: 10.1016/j.ijrobp.2021.06.03734711459)
      Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschold P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88:339–44. (PMID: 10.1016/j.ijrobp.2013.10.042244116064581453)
      Zilli T, Jorcano S, Bral S, Rubio C, Bruynzeel AME, Oliveira A, et al. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Cancer Med. 2020;9:3097–106. (PMID: 10.1002/cam4.2966321604167196054)
      Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2020;142:62–71. (PMID: 10.1016/j.radonc.2019.10.017317674737005673)
      ESTRO. Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). ESTRO 2021; Madrid, 2021.
      Kishan AU, Lamb J, Casado M, Wang X, Ma TM, Low D, et al. Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): interim analysis of a phase III randomized trial. J Clin Oncol. 2022;40:255–255. (PMID: 10.1200/JCO.2022.40.6_suppl.255)
    • Publication Date:
      Date Created: 20220429 Date Completed: 20230321 Latest Revision: 20230824
    • Publication Date:
      20240829
    • Accession Number:
      10.1038/s41391-022-00535-4
    • Accession Number:
      35488121